English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/168850
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Synergistic DNA-damaging effect in multiple myeloma with the combination of zalypsis, bor tezomib and dexamethasone

AuthorsLópez-Iglesias, Ana-Alicia; González-Méndez, Lorena; San-Segundo, Laura; Herrero, Ana B.; Hernández-García, Susana; Martín-Sánchez, Montserrat; Gutiérrez, Norma Carmen; Paíno, Teresa ; Avilés Marín, Pablo; Mateos, Maria Victoria; San Miguel, Jesús F. ; Garayoa, Mercedes ; Ocio, Enrique M.
Issue Date2017
PublisherFerrata Storti Foundation
CitationHaematologica 102(1): 168-175 (2017)
AbstractDespite new advances in multiple myeloma treatment and the consequent improvement in overall survival, most patients relapse or become refractory to treatment. This suggests that new molecules and combinations that may further inhibit important survival pathways for these tumor cells are needed. In this context, zalypsis is a novel compound, derived from marine organisms, with a powerful preclinical anti-myeloma effect based on the sensitivity of malignant plasma cells to DNA-damage induction; and it has already been tested in a phase I/II clinical trial in multiple myeloma. We hypothesized that the addition of this compound to the combination of bortezomib plus dexamethasone may improve efficacy with acceptable toxicity. The triple combination demonstrated strong synergy and higher efficacy compared with double combinations; not only in vitro, but also ex vivo and, especially, in in vivo experiments. The triple combination triggers cell death, mainly through a synergistic induction of DNA damage and a decrease in the nuclear localization of nuclear factor kappa B. Our findings support the clinical evaluation of this combination for relapsed and refractory myeloma patients.
Publisher version (URL)https://doi.org/10.3324/haematol.2016.146076
Identifiersdoi: 10.3324/haematol.2016.146076
e-issn: 1592-8721
issn: 0390-6078
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
ZaBDeFinalversion.pdf2,34 MBAdobe PDFThumbnail
Supplemental Data final version.pdf1,1 MBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.